BEONE MEDICINES LTD (ONC)

Q: What's priced into BEONE MEDICINES LTD (ONC) stock?

ONC trades at a premium to peers, and the valuation evidence points to an expensive setup. The expectations gap is slightly negative, but the model confidence is low and the priced-in assessment is tagged as justified, with no fragility gates triggered.

Q: What does the BEONE MEDICINES LTD (ONC) outlook hinge on?

The multi-year thesis depends on continued BRUKINSA global growth and delivery of the raised operating income guidance. A guidance reversal would damage management credibility, while weakening jobs data could raise recession concerns for cyclical names. Continued earnings strength and higher guidance from healthcare peers such as VRTX, REGN, and MRNA would support the sector backdrop.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$377.63-1.21%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge BEONE MEDICINES LTD’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.3%

+10% or more+5%0%−5%−10% or less

10.04 → 10.00 EPS · FY ending Dec 31, 2027 · 11 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 12 to 11; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.79B
EPS	—	1.612
FY 2026 · Annual
Revenue	$6.6B–$6.8B	6.78B
EPS	—	7.275
Operating income	$1.7B–$1.8Bnon-GAAP $1B–$1.1BGAAP	—
FY 2027 · Annual
Revenue	—	7.81B
EPS	—	10.005

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain gross margin near 80% in FY26	A primary condition in BEONE MEDICINES LTD's published investment case. The stated target is around 80%.	Intact	gross margin falls below 75% in FY26	Gross margin: 89.76% FY2026-Q2; GAAP. Published target: around 80%. Target period is not explicitly aligned with this observation. Source published Aug 5, 202689.764063 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ea947ad7-19d0-4472-b370-3624884cd6bb. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. GAAP gross margin improved from 89% in 2026-Q1 to 90% in 2026-Q2, exceeding the high-80% range guidance for full year 2026. Management's focus on product mix and productivity improvements is reflected in the improving margin trajectory, delivering on this cost efficiency priority. Delivery assessment Oct 24, 2026
Reach operating income of $750-$850 million in FY26	Operating income rises toward $750-$850M.	Intact	operating income falls below $700M in FY26	Operating income: $325.047M FY2026-Q2; GAAP. Published target: >= $750M and <= $850M. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026325,047,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ea947ad7-19d0-4472-b370-3624884cd6bb. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance three programs to Phase 3 trials by mid-2026	A supporting condition in BEONE MEDICINES LTD's published investment case. The stated target is three programs in Phase 3 by mid-2026.	Intact	failure to advance key programs to Phase 3 by mid-2026	3 programs in Phase 3 vs target 3 by mid-2026 News from June 2026 states three programs are near Phase 3, aligning with the thesis target. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve revenue of $6.3-$6.5 billion in FY26	A primary condition in BEONE MEDICINES LTD's published investment case. The stated target is >= $6.3B and <= $6.5B.	Intact	revenue falls below $6.3B in FY26	Revenue: $1.705B FY2026-Q2; GAAP. Published target: >= $6.3B and <= $6.5B. Target period is not explicitly aligned with this observation. Source published Aug 5, 20261,705,071,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: ea947ad7-19d0-4472-b370-3624884cd6bb. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. BRUKINSA global revenues increased from $1.1 billion in 2026-Q1 to $1.2 billion in 2026-Q2, representing 31% year-over-year growth in Q2. Management consistently emphasizes BRUKINSA's leadership and global expansion, and the revenue trajectory is delivering on this growth priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$10.00

$9.81 → $10.00 · observed estimates

FY2027 revenue$7.81B

$7.52B → $7.81B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.81	$7,523,682,875	11 / 23
2026-07-25	$9.68	$7,454,306,940	16 / 34
2026-07-26	$9.68	$7,454,306,940	16 / 34
2026-07-27	$9.68	$7,454,306,940	16 / 34
2026-07-28	$9.68	$7,454,306,940	16 / 34
2026-07-29	$9.68	$7,454,306,940	16 / 34
2026-07-30	$9.68	$7,454,306,940	16 / 34
2026-07-31	$9.81	$7,527,751,532	11 / 23
2026-08-01	$9.81	$7,527,751,532	11 / 23
2026-08-02	$9.69	$7,454,306,940	15 / 34
2026-08-03	$9.81	$7,527,751,532	11 / 23
2026-08-04	$9.69	$7,454,306,940	15 / 34
2026-08-05	$9.81	$7,527,751,532	11 / 23
2026-08-06	$9.81	$7,527,751,532	11 / 23
2026-08-07	$9.94	$7,662,035,630	11 / 23
2026-08-08	$10.15	$7,663,309,080	15 / 32
2026-08-09	$10.15	$7,663,309,080	15 / 32
2026-08-10	$10.15	$7,663,309,080	15 / 32
2026-08-12	$10.29	$7,694,431,450	16 / 31
2026-08-13	$9.94	$7,662,035,630	11 / 23
2026-08-14	$9.94	$7,662,035,630	11 / 23
2026-08-15	$9.94	$7,662,035,630	11 / 23
2026-08-16	$9.94	$7,662,035,630	11 / 23
2026-08-17	$9.94	$7,662,035,630	11 / 23
2026-08-18	$9.94	$7,662,035,630	11 / 23
2026-08-19	$9.94	$7,662,035,630	11 / 23
2026-08-20	$9.97	$7,811,442,558	12 / 23
2026-08-21	$9.97	$7,811,442,558	12 / 23
2026-08-22	$9.97	$7,811,442,558	12 / 23
2026-08-23	$9.97	$7,811,442,558	12 / 23
2026-08-24	$9.97	$7,811,442,558	12 / 23
2026-08-25	$10.11	$7,797,489,254	12 / 23
2026-08-26	$10.11	$7,797,489,254	12 / 23
2026-08-27	$10.11	$7,797,489,254	12 / 23
2026-08-28	$10.11	$7,797,489,254	12 / 23
2026-08-29	$10.11	$7,797,489,254	12 / 23
2026-08-30	$10.11	$7,797,489,254	12 / 24
2026-08-31	$10.11	$7,797,489,254	12 / 24
2026-09-01	$10.14	$7,804,399,219	12 / 24
2026-09-02	$10.14	$7,804,383,025	12 / 24
2026-09-03	$10.14	$7,804,383,025	12 / 24
2026-09-04	$10.14	$7,804,383,025	12 / 24
2026-09-05	$10.14	$7,804,383,025	12 / 24
2026-09-06	$10.14	$7,804,383,025	12 / 24
2026-09-07	$10.14	$7,804,383,025	12 / 24
2026-09-08	$10.14	$7,804,383,025	12 / 24
2026-09-09	$10.14	$7,804,383,025	12 / 24
2026-09-10	$10.16	$7,804,383,025	12 / 24
2026-09-11	$10.16	$7,804,383,025	12 / 24
2026-09-12	$10.16	$7,804,383,025	12 / 24
2026-09-13	$10.16	$7,804,383,025	12 / 24
2026-09-14	$10.16	$7,804,433,025	12 / 24
2026-09-15	$10.04	$7,804,433,025	12 / 24
2026-09-16	$10.04	$7,804,433,025	12 / 24
2026-09-17	$10.04	$7,804,433,025	12 / 24
2026-09-18	$10.04	$7,804,433,025	12 / 24
2026-09-19	$10.04	$7,804,433,025	12 / 24
2026-09-20	$10.04	$7,804,433,025	12 / 24
2026-09-21	$10.04	$7,804,433,025	12 / 24
2026-09-22	$10.04	$7,804,433,025	12 / 24
2026-09-23	$10.04	$7,804,433,025	12 / 24
2026-09-24	$10.04	$7,804,433,025	12 / 24
2026-09-25	$10.04	$7,804,433,025	12 / 24
2026-09-26	$10.04	$7,804,433,025	12 / 24
2026-09-27	$10.04	$7,804,433,025	12 / 24
2026-09-28	$10.04	$7,804,433,025	12 / 24
2026-09-29	$10.03	$7,807,734,938	12 / 24
2026-09-30	$10.03	$7,807,734,938	12 / 24
2026-10-01	$10.03	$7,807,734,938	12 / 23
2026-10-02	$10.00	$7,802,134,938	12 / 23
2026-10-03	$10.00	$7,802,134,938	12 / 23
2026-10-04	$10.00	$7,802,134,938	12 / 23
2026-10-05	$10.00	$7,802,134,938	12 / 23
2026-10-06	$10.00	$7,802,124,824	12 / 23
2026-10-07	$10.00	$7,802,124,824	12 / 23
2026-10-08	$10.00	$7,803,807,624	12 / 22
2026-10-09	$10.00	$7,803,321,910	12 / 22
2026-10-10	$10.00	$7,803,321,910	12 / 22
2026-10-11	$10.00	$7,803,321,910	12 / 22
2026-10-12	$10.00	$7,803,321,910	12 / 22
2026-10-13	$10.00	$7,803,321,910	12 / 22
2026-10-14	$10.00	$7,808,933,782	12 / 22
2026-10-15	$10.00	$7,808,933,782	12 / 22
2026-10-16	$10.00	$7,812,311,943	12 / 22
2026-10-17	$10.00	$7,812,311,943	12 / 22
2026-10-18	$10.00	$7,812,311,943	11 / 22
2026-10-19	$10.00	$7,812,311,943	11 / 22
2026-10-20	$10.00	$7,812,311,943	11 / 22
2026-10-21	$10.00	$7,812,311,943	12 / 22
2026-10-22	$10.00	$7,812,311,943	12 / 22
2026-10-23	$10.00	$7,812,311,943	11 / 22
2026-10-24	$10.00	$7,812,311,943	11 / 22

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	27	1
2026-06-01	27	1
2026-07-01	28	1
2026-08-01	28	1
2026-09-01	27	1
2026-10-01	27	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 27 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 16 · prior May 7

$395.00 → $425.00+7.6%

RBC CapitalOct 8 · prior Jul 7

$451.00 → $459.00+1.8%

Truist FinancialOct 7 · prior Jul 7

$416.00 → $420.00+1.0%

$0$252.45$504.90

3 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain gross margin near 80% in FY26Gross margin: 89.76%
Reach operating income of $750-$850 million in FY26Operating income: $325.047M
Achieve revenue of $6.3-$6.5 billion in FY26Revenue: $1.705B

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.4%Typical daily move · historical

Downside history

-31.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BEONE MEDICINES LTD outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented biopharmaceutical business with recent strong financial performance, but it is not yet consistently profitable on an earnings-quality basis. The multi-year view remains intact, while the signal has softened from favorable to mildly favorable.

What's priced into BEONE MEDICINES LTD

ONC trades at a premium to peers, and the valuation evidence points to an expensive setup. The expectations gap is slightly negative, but the model confidence is low and the priced-in assessment is tagged as justified, with no fragility gates triggered.

What the fundamentals likely do

Near term, recent earnings beats and stronger results support the business setup. BRUKINSA revenue grew 31% year over year in the second quarter, gross margin reached 90%, and management raised 2026 operating income guidance to $1.0 billion to $1.1 billion. Execution is on track against stated priorities, but erratic earnings surprises and a recent shift to a mildly favorable signal temper confidence.

What BEONE MEDICINES LTD hinges on

The multi-year thesis depends on continued BRUKINSA global growth and delivery of the raised operating income guidance. A guidance reversal would damage management credibility, while weakening jobs data could raise recession concerns for cyclical names. Continued earnings strength and higher guidance from healthcare peers such as VRTX, REGN, and MRNA would support the sector backdrop.

Bottom line

Over the next 1 to 3 years, ONC’s long-term thesis has support from product growth, improving margins, and rising operating income, but its expensive valuation and loss-making earnings profile leave execution as the key test. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.79B
EPS	—	1.612
FY 2026 · Annual
Revenue	$6.6B–$6.8B	6.78B
EPS	—	7.275
Operating income	$1.7B–$1.8Bnon-GAAP $1B–$1.1BGAAP	—
FY 2027 · Annual
Revenue	—	7.81B
EPS	—	10.005

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$10.00

$9.81 → $10.00 · observed estimates

FY2027 revenue$7.81B

$7.52B → $7.81B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.81	$7,523,682,875	11 / 23
2026-07-25	$9.68	$7,454,306,940	16 / 34
2026-07-26	$9.68	$7,454,306,940	16 / 34
2026-07-27	$9.68	$7,454,306,940	16 / 34
2026-07-28	$9.68	$7,454,306,940	16 / 34
2026-07-29	$9.68	$7,454,306,940	16 / 34
2026-07-30	$9.68	$7,454,306,940	16 / 34
2026-07-31	$9.81	$7,527,751,532	11 / 23
2026-08-01	$9.81	$7,527,751,532	11 / 23
2026-08-02	$9.69	$7,454,306,940	15 / 34
2026-08-03	$9.81	$7,527,751,532	11 / 23
2026-08-04	$9.69	$7,454,306,940	15 / 34
2026-08-05	$9.81	$7,527,751,532	11 / 23
2026-08-06	$9.81	$7,527,751,532	11 / 23
2026-08-07	$9.94	$7,662,035,630	11 / 23
2026-08-08	$10.15	$7,663,309,080	15 / 32
2026-08-09	$10.15	$7,663,309,080	15 / 32
2026-08-10	$10.15	$7,663,309,080	15 / 32
2026-08-12	$10.29	$7,694,431,450	16 / 31
2026-08-13	$9.94	$7,662,035,630	11 / 23
2026-08-14	$9.94	$7,662,035,630	11 / 23
2026-08-15	$9.94	$7,662,035,630	11 / 23
2026-08-16	$9.94	$7,662,035,630	11 / 23
2026-08-17	$9.94	$7,662,035,630	11 / 23
2026-08-18	$9.94	$7,662,035,630	11 / 23
2026-08-19	$9.94	$7,662,035,630	11 / 23
2026-08-20	$9.97	$7,811,442,558	12 / 23
2026-08-21	$9.97	$7,811,442,558	12 / 23
2026-08-22	$9.97	$7,811,442,558	12 / 23
2026-08-23	$9.97	$7,811,442,558	12 / 23
2026-08-24	$9.97	$7,811,442,558	12 / 23
2026-08-25	$10.11	$7,797,489,254	12 / 23
2026-08-26	$10.11	$7,797,489,254	12 / 23
2026-08-27	$10.11	$7,797,489,254	12 / 23
2026-08-28	$10.11	$7,797,489,254	12 / 23
2026-08-29	$10.11	$7,797,489,254	12 / 23
2026-08-30	$10.11	$7,797,489,254	12 / 24
2026-08-31	$10.11	$7,797,489,254	12 / 24
2026-09-01	$10.14	$7,804,399,219	12 / 24
2026-09-02	$10.14	$7,804,383,025	12 / 24
2026-09-03	$10.14	$7,804,383,025	12 / 24
2026-09-04	$10.14	$7,804,383,025	12 / 24
2026-09-05	$10.14	$7,804,383,025	12 / 24
2026-09-06	$10.14	$7,804,383,025	12 / 24
2026-09-07	$10.14	$7,804,383,025	12 / 24
2026-09-08	$10.14	$7,804,383,025	12 / 24
2026-09-09	$10.14	$7,804,383,025	12 / 24
2026-09-10	$10.16	$7,804,383,025	12 / 24
2026-09-11	$10.16	$7,804,383,025	12 / 24
2026-09-12	$10.16	$7,804,383,025	12 / 24
2026-09-13	$10.16	$7,804,383,025	12 / 24
2026-09-14	$10.16	$7,804,433,025	12 / 24
2026-09-15	$10.04	$7,804,433,025	12 / 24
2026-09-16	$10.04	$7,804,433,025	12 / 24
2026-09-17	$10.04	$7,804,433,025	12 / 24
2026-09-18	$10.04	$7,804,433,025	12 / 24
2026-09-19	$10.04	$7,804,433,025	12 / 24
2026-09-20	$10.04	$7,804,433,025	12 / 24
2026-09-21	$10.04	$7,804,433,025	12 / 24
2026-09-22	$10.04	$7,804,433,025	12 / 24
2026-09-23	$10.04	$7,804,433,025	12 / 24
2026-09-24	$10.04	$7,804,433,025	12 / 24
2026-09-25	$10.04	$7,804,433,025	12 / 24
2026-09-26	$10.04	$7,804,433,025	12 / 24
2026-09-27	$10.04	$7,804,433,025	12 / 24
2026-09-28	$10.04	$7,804,433,025	12 / 24
2026-09-29	$10.03	$7,807,734,938	12 / 24
2026-09-30	$10.03	$7,807,734,938	12 / 24
2026-10-01	$10.03	$7,807,734,938	12 / 23
2026-10-02	$10.00	$7,802,134,938	12 / 23
2026-10-03	$10.00	$7,802,134,938	12 / 23
2026-10-04	$10.00	$7,802,134,938	12 / 23
2026-10-05	$10.00	$7,802,134,938	12 / 23
2026-10-06	$10.00	$7,802,124,824	12 / 23
2026-10-07	$10.00	$7,802,124,824	12 / 23
2026-10-08	$10.00	$7,803,807,624	12 / 22
2026-10-09	$10.00	$7,803,321,910	12 / 22
2026-10-10	$10.00	$7,803,321,910	12 / 22
2026-10-11	$10.00	$7,803,321,910	12 / 22
2026-10-12	$10.00	$7,803,321,910	12 / 22
2026-10-13	$10.00	$7,803,321,910	12 / 22
2026-10-14	$10.00	$7,808,933,782	12 / 22
2026-10-15	$10.00	$7,808,933,782	12 / 22
2026-10-16	$10.00	$7,812,311,943	12 / 22
2026-10-17	$10.00	$7,812,311,943	12 / 22
2026-10-18	$10.00	$7,812,311,943	11 / 22
2026-10-19	$10.00	$7,812,311,943	11 / 22
2026-10-20	$10.00	$7,812,311,943	11 / 22
2026-10-21	$10.00	$7,812,311,943	12 / 22
2026-10-22	$10.00	$7,812,311,943	12 / 22
2026-10-23	$10.00	$7,812,311,943	11 / 22
2026-10-24	$10.00	$7,812,311,943	11 / 22

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings